Revista de Antivirales y Antirretrovirales
Acceso abierto
ISSN: 1948-5964
ISSN: 1948-5964
Umut Devrim Binay, Faruk Karakecili, Orcun Barkay, Ozlem Gul, Cuma Mertoglu
Background: It is necessary to use an effective vaccine to end the COVID-19 pandemic. CoronaVac vaccine is used in our country and we aimed to examine the level of antibody development after the first dose.
Methods: This is a retrospective, cross-sectional research. The data of the people, who applied to a university hospital between January and February 2021,were analyzed. Those who had SARS-CoV-2 IgG and IgM measurement in the previous two weeks before the CoronoVac vaccine, and those who were both found negative and who had SARS-CoV-2 IgG and IgM measurement after the first dose of CoronaVac vaccine were included in the research. SARS-CoV-2 IgG/IgM were measured by VIDAS® (BioMérieux, Marcy-l'Etoile, France) device for the detection of spike protein specific IgG/IgM of SARS-CoV-2 in human serum with ELFA (Enzyme Linked Fluorescent Assay) technique.
Results: 30 people were included in this research. It was found that the individuals had SARS-CoV-2 IgG and IgM measurements between 14 and 21 days after the first dose of CoronaVac vaccine. It was observed that 30% (n=9) of the cases had a history of COVID-19.The rate of positivity for SARS CoV-2 IgG level after vaccination was 40% (n=12/30) and it was 77.8% (n=7/9) in cases with a history of COVID-19 and it was significantly higher than those without a history of COVID-19 (p=0.013).
Conclusions: A single dose of CoronaVac vaccine is not enough, but perhaps a single dose of vaccination may be sufficient for those who have had COVID-19.